
Sign up to save your podcasts
Or


Novo Nordisk can't keep up with demand for Ozempic and Wegovy, giving competitor Eli Lilly the edge in the GLP-1 market. And off-brand competitors continue to hammer the company's market position. Layoffs and board resignations signal that Novo Nordisk has entered a downward spiral. But with new leaders, acquisitions and deals, can they force a comeback?
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
By Audible4.6
1255912,559 ratings
Novo Nordisk can't keep up with demand for Ozempic and Wegovy, giving competitor Eli Lilly the edge in the GLP-1 market. And off-brand competitors continue to hammer the company's market position. Layoffs and board resignations signal that Novo Nordisk has entered a downward spiral. But with new leaders, acquisitions and deals, can they force a comeback?
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

30,666 Listeners

10,430 Listeners

30,185 Listeners

777 Listeners

466 Listeners

19,280 Listeners

2,144 Listeners

19,168 Listeners

2,149 Listeners

116 Listeners

3,045 Listeners

22,963 Listeners

11,076 Listeners

904 Listeners

1,460 Listeners

7,782 Listeners

255 Listeners

2,575 Listeners

251 Listeners

2,158 Listeners

7,343 Listeners

855 Listeners

1,529 Listeners

241 Listeners

626 Listeners

70 Listeners

536 Listeners

876 Listeners

170 Listeners